This study showed that GPS is effective in improving the phenotype of HFHC-induced NASH mice, including reducing body weight gain and liver weight, decreasing serum levels of ALT, TG, TC, and LDL-C, and improving insulin sensitivity, as well as attenuating hepatic steatosis. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.